103 related articles for article (PubMed ID: 4054202)
1. Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.
Trillet V; Lakhal M; Lang J; Perrin-Fayolle E; Timour Chah Q; Fière D; Faucon G
Eur J Clin Pharmacol; 1985; 29(1):127-9. PubMed ID: 4054202
[TBL] [Abstract][Full Text] [Related]
2. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
Paul C; Baurain R; Gahrton G; Peterson C
Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
[TBL] [Abstract][Full Text] [Related]
3. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
[TBL] [Abstract][Full Text] [Related]
4. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.
Andersson B; Beran M
Cancer Chemother Pharmacol; 1980; 4(3):205-7. PubMed ID: 7397945
[TBL] [Abstract][Full Text] [Related]
5. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
Paul C; Peterson C; Gahrton G; Lockner D
Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
[TBL] [Abstract][Full Text] [Related]
6. Uptake and metabolism of daunorubicin by human leukemia cells.
DeGregorio MW; Carrera CJ; Klock JC; Wilbur JR
Cancer Chemother Pharmacol; 1982 Dec; 10(1):29-32. PubMed ID: 6961971
[TBL] [Abstract][Full Text] [Related]
7. Effect of cyclophosphamide pretreatment on daunorubicin in rat acute leukaemia model.
Nooter K; de Vries A; Martens AC; Hagenbeek A
Eur J Cancer; 1990; 26(6):729-32. PubMed ID: 2144163
[TBL] [Abstract][Full Text] [Related]
8. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.
Speth PA; van de Loo FA; Linssen PC; Wessels HM; Haanen C
Clin Pharmacol Ther; 1986 Dec; 40(6):643-9. PubMed ID: 3465490
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia].
Sun YN; Chai YH; Xu YJ; Lü H
Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):296-300. PubMed ID: 19555570
[TBL] [Abstract][Full Text] [Related]
10. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacokinetics of daunomycin administered as continuous intravenous infusion in the treatment of acute non-lymphocytic leukaemia.
Speth PA; Linssen PC; de Pauw BE; de Witte TJ
Br J Haematol; 1986 Jul; 63(3):602-5. PubMed ID: 3730289
[No Abstract] [Full Text] [Related]
12. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.
Ganapathi R; Gulick P; Miller R; Grabowski D; Turinic R; Valeunzuela R; Fishleder A; Bukowski R
Invest New Drugs; 1985; 3(3):273-7. PubMed ID: 3864764
[TBL] [Abstract][Full Text] [Related]
13. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.
Xu D; Knaust E; Pisa P; Palucka K; Lundeberg J; Areström I; Peterson C; Gruber A
Br J Haematol; 1996 Mar; 92(4):847-54. PubMed ID: 8616077
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and sensitivity of daunorubicin in patients with acute leukemia.
DeGregorio MW; Holleran WM; Macher BA; Linker CA; Wilbur JR
Cancer Chemother Pharmacol; 1984; 13(3):230-4. PubMed ID: 6488444
[TBL] [Abstract][Full Text] [Related]
15. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.
Nilsson SO; Andersson B; Eksborg S; Beran M; Ehrsson H
Cancer Chemother Pharmacol; 1981; 5(4):261-6. PubMed ID: 7261253
[TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
18. Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.
Baurain R; Zenebergh A; Trouet A
J Chromatogr; 1978 Sep; 157():331-6. PubMed ID: 568150
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Haematologica; 2000 Feb; 85(2):124-32. PubMed ID: 10681718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
